NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023 (NASDAQ:NAMS)

Shot of a doctor examining a patient with a stethoscope during a consultation in a hospital


Q2 earnings summary – Maintaining a Buy Rating on NAMS

Although we had written an article recently before the earnings where we focused on the evolving landscape of LDL-c lowering therapies, we decided to write a follow-up article

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *